Antitumor and cellular pharmacological properties of a novel platinum(IV) complex: Trans-[PtCl2(OH)2(dimethylamine) (isopropylamine)]

Molecular Pharmacology

Volumn 63, Issue 4, 2003, Pages 933-944

  Pérez, José M ^a   Kelland, Lloyd R ^b   Montero, Eva I ^a   Boxall, Frances E ^b   Fuertes, Miguel A ^a   Alonso, Carlos ^a   Navarro Ranninger, Carmen ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; CISPLATIN; DIMETHYLAMINE; PLASMA PROTEIN; PLATINUM COMPLEX; PROPYLAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CELL COUNT; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DNA CROSS LINKING; DNA REPAIR; DNA STRAND; DRUG ACTIVITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERANCE; EXTRACELLULAR SPACE; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; CELL DIVISION; DISEASE MODELS, ANIMAL; DNA; DNA ADDUCTS; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; ORGANOPLATINUM COMPOUNDS; PLASMIDS; PLATINUM; SERUM ALBUMIN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037380819     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.63.4.933     Document Type: Article

References (39)

1. Alley MC, Scudiero DA, Monks A, Hurshey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, and Boyd MR (1988) Feasibility of Drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:589-601.
2. Alvarez-Valdés A, Pérez JM, López-Solera I, Lannegrand R, Continente JM, Amo-Ochoa P, Camazón MJ, Solans X, Font-Bardía M, and Navarro-Ranninger C (2002) Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells. J Med Chem 45:1835-1844.
3. Cohen SM and Lippard SJ (2001) Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 67:93-130.
4. Connors TA, Cleare MJ, and Harrap KR (1979) Structure-activity relationships of the antitumor platinum coordination complexes. Cancer Treat Rep 63:1499-1502.
5. Farrell N (1993) Nonclassical platinum antitumor agents: perspectives for design and development ofnew drugs complementary to cisplatin. Cancer Invest 11:578-589.
6. Farrell N, Ha TTB, Souchard JP, Wimmer FL, Cros S, and Johnson NP (1989) Cytostatic trans-platinum(II) complexes. J Med Chem 32:2240-2241.
7. Fernández-Ruíz R, Tornero JD, González VM, and Alonso C (1999) Quantification of Pt bound to DNA using total-reflection X-ray fluorescence (TXRF). Analyst 124:583-585.
8. Fuertes MA, Castilla J, Alonso C, and Pérez JM (2002) Novel concepts in the development of platinum antitumor drugs. Curr Med Chem Anti-Cancer Agents 2:539-541.
9. Fuertes MA, Castilla J, Alonso C, and Pérez JM (2003) Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem 10:1241-1253.
10. Fuertes MA, Pérez JM, Soto M, López MC, and Alonso C (2001) Calcium-induced conformational changes in Leishmania infantum kinetoplastid membrane protein-11. J Biol Inorg Chem 6:107-117.
11. González VM, Fuertes MA, Alonso C, and Pérez JM (2001) Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 59:657-663.
12. 2O complex inhibits the B to Z transition. Mol Pharmacol 85:770-778.
13. Gowan SM, Harrison JR, Patterson L, Valenti M, Read MA, Neidle S, and Kelland LR (2002) A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antiumor activity. Mol Pharmacol 61:1154-1162.
14. Hills CA, Kelland LR, Abel G, Siracky J, Wilson AP, and Harrap KR (1989) Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer 59:527-534.
15. Judson I, Cerny T, Epelbaum R, Dunlop D, Smyth J, Schaefer B, Roelvink M, Kaplan S, and Hanauske A (1997) Phase II trial of the oral platinum complex JM216 in non-small cell lung cancer: an EORTC early clinical studies group investigation. Ann Oncol 8:604-606.
16. Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, and Harrap KR (1993) Preclinical antitumor evaluation of bis-acetato-amminedichloro cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res 53:2581-2586.
17. Kelland LR, Barnard CFJ, Evans IG, Murrer BA, Theobald BRC, Wyer SB, Goddard PM, Jones M, Valenti M, Bryant A, et al. (1995) Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes. J Med Chem 38:3016-3024.
18. Kelland LR, Barnard CFJ, Mellish KJ, Jones M, Goddard PM, Valenti M, Bryant A, Murrer BA, and Harrap KR (1994) A novel trans-platinum coordination complex possseing in vitro and in vivo antitumor activity. Cancer Res 54:5618-5622.
19. Kelland LR, Mistry P, Abel G, Loh SY, O'Neill CF, Murrer BA, and Harrap KR (1992) Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res 52:3857-3864.
20. 3 by an iminoether in transplatin makes an antitumor drug from an inactive compound. Mol Pharmacol 58:1525-1535.
21. Maniatis T, Fritsch EF, and Sambrook J (1989) Plasmid vectors, in Molecular Cloning: A Laboratory Manual (Nolan C ed) vol 1, pp 1-109. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
22. 2(amine)(isopropylamine) compounds: cytotoxic activity and apoptosis induction in ras-transformed cells. J Med Chem 42:4264-4268.
23. 2]: cross-linking between d(G) and complementary d(G) within oligonucleotide duplexes. ChemBio-Chem 3:101-107.
24. Natile G and Coluccia M (2001) Current status of trans-platinum compounds in cancer therapy. Coord Chem Rev 216:383-410.
25. O'Dwyer PJ, Stevenson JP, and Johnson SW (2000) Clinical Pharmacokinetics and administration of established platinum drugs. Drugs 59:19-27.
26. 2(isopropylamine)(amine')] compounds: cytotoxic activity and reactions with 5′-GMP compared with their transplatinum isomers. Inorg Chim Acta 339:525-531.
27. Pérez JM, Fuertes MA, Alonso C, and Navarro-Ranninger C (2000a) Current status of the development of trans-platinum antitumor drugs. Crit Rev Oncol Hematol 35:109-120.
28. 2 (isopropylamine) (amine')] complexes. J Inorg Biochem 77:37-42.
29. 2(dimethylamine)(isopropylamine)]: interstrand cross-link efficiency, DNA sequence specificity, and inhibition of the B-Z transition. J Med Chem 43:2411-2418.
30. 2(N, N-dimethylamine)(isopropylamine)] in A2780cisR ovarian tumor cells. Metal Based Drugs 8:29-37.
31. Pérez RP (1998) Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34:1535-1544.
32. Pestell KE, Hobbs SM, Titley JC, Kelland LR, and Walton MI (2000) Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line: Mol Pharmacol 57:503-511.
33. Petersen LN, Mamenta EL, Stevnsner T, Chaney SG, and Bohr VA (1996) Increased gene specific repair of cisplatin induced interstrand crosslinks in cisplatin resistant cell lines and studies on carrier ligand specificity. Carcinogenesis 17:2597-2602.
34. Trynda-Lemiesz L, Kozlowski H, and Keppler BK (1999) Effect of cis-, transdiamminedichloroplatinum(II) and DBP on human serum albumin. J Inorg Biochem 77:141-146.
35. Van Engeland M, Nieland LJW, Ramaekers FCS, Schutte B, and Reutenlingsperger CPM (1998) Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 31:1-9.
36. Wong E and Giandomenico CM (1999) Current status of platinum-based antitumor drugs. Chem Rev 99:2451-2466.
37. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, et al (1999) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 77:1-10.
38. Zdraveski ZZ, Mello JA, Farinelli CK Essigmann JM, and Marinus MG (2002) MutS preferentially recognizes cisplatin-over oxaliplatin-modified DNA. J Biol Chem 277:1255-1260.
39. Zhang JS, Imai T, Suenaga A, and Otagiri M (2002) Molecular-weight-dependent pharmacokinetics and cytotoxic properties of cisplatin complexes prepared with chondroitin sulphate A and C. Int J Pharm 240:23-31.